Aerie Pharmaceuticals, Inc. (Aerie Pharmace) Stock Price & News | AERI
Aerie Pharmaceuticals Using ROCK Inhibitors to Change Glaucoma Management | Ophthalmology Innovation Source
Aerie Pharmaceuticals Inc - Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before
Rhopressa enrolled in second Phase 3 registration trial
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of
Aerie to build manufacturing facility in Ireland
Aerie Pharmaceuticals
Santen Expands License Agreement with Aerie for Rhopressa and Rocklatan | Market Scope
Articles about Aerie Pharmaceuticals, Inc. | page 5
Aerie Pharmaceuticals CEO discusses what's new in the pipeline
Glaucoma Physician - February 12, 2021
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions — Duke OTC
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions | Business Wire
Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma to Advance Its Dry Eye Program | World Pharma Today
EX-99.1
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% | Business Wire
Aerie Pharmaceuticals, Inc. — Duke OTC
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
Form 8-K AERIE PHARMACEUTICALS For: Jan 12
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease | Business Wire
Aerie Pharmaceuticals (Nasdaq: AERI) cleared to begin clinical testing for dry eye treatment - Triangle Business Journal
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% | Business Wire
AERIE PHARMACEUTICALS, INC. NPS 2022
EX-99.1
